Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) today announced that the independent Data Safety Monitoring Board (DSMB) of SEAMLESS, recommended that the Phase 3, randomized, registration-directed study of sapacitabine in elderly patients with acute myeloid leukemia (AML) should enter the randomized stage as planned. Judy H. Chiao , M.D., Vice President, Clinical Development and Regulatory Affairs of […]
Home» Posts tagged "CYCC"
07.07.2011 After-Hours News: CYCC, CRMD, ECTY & ADHC
Cyclacel Pharmaceuticals, Inc. Announces Closing of Underwritten Offering of Common Stock and Warrants BERKELEY HEIGHTS, N.J. , July 7, 2011 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that it has closed its previously announced underwritten offering of an aggregate of 7,617,646 units at an offering price of $1.36 […]